D-0159-2026 Class II Ongoing

Recalled by Zydus Pharmaceuticals (USA) Inc — Pennington, NJ

FDA drug recall D-0159-2026 was initiated by Zydus Pharmaceuticals (USA) Inc on Oct 23, 2025 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules. The recall status is ongoing. Affected quantity: 36,624 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 26, 2025
Initiation Date
Oct 23, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
36,624 bottles

Product description

Bromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India. Distributed by: Zydus Pharmaceuticals, Pennington, NJ 08534. NDC 68382-110-06

Reason for recall

Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.

Distribution pattern

Nationwide in the USA

Code information

Lot #: M313934, M313935, M315615, Exp. Date Nov 2025; M316809 , Exp. Date Dec-25; M405765, M405763, M405764, Exp. Date Apr-26; M414999, M414241, M414307, M414305, Exp. Date Oct-26

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0159-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0159-2026. Report a data issue: hello@regdatalab.com.